Greater Cannabis Company (GCAN) Receivables (2020 - 2021)
Greater Cannabis Company's (GCAN) quarterly Receivables came in at $36750.0 in Q3 2021, up 55.89% year-on-year from $23575.0 in Q3 2020, and little changed quarter-over-quarter from $36750.0 in Q2 2021.
Greater Cannabis Company (GCAN) Receivables (2020 - 2021) Analysis & Trends
Greater Cannabis Company's Receivables history runs 2 years deep, the most recent figure standing at $36750.0 for Q3 2021.
- On a quarterly basis, Receivables rose 55.89% year-over-year to $36750.0 in Q3 2021; TTM through Sep 2021 was $36750.0, a 55.89% increase from a year earlier, with the FY2020 full-year figure at $36750.0, changed N/A from the prior year.
- Receivables steadied at $36750.0 in Q3 2021 per GCAN's latest filing, from $36750.0 in the prior quarter.
- Across five years, Receivables topped out at $36750.0 in Q4 2020 and bottomed at $23575.0 in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 2.99 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 3.39 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 1.51 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 6.46 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 312.00 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 15.29 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 3.58 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 768.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.15 Bn |
| 10 | Greater Cannabis Company | 292,929.85 | 292,929.85 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 36,750.00 |
| Jun 30, 2021 | 36,750.00 |
| Mar 31, 2021 | 36,750.00 |
| Dec 31, 2020 | 36,750.00 |
| Sep 30, 2020 | 23,575.00 |
| Jun 30, 2020 | 23,575.00 |